The efficacy of nucleosides plus artificial liver support system on treating chronic severe hepatitis
摘要: 研究核苷类似物联合人工肝治疗慢性乙型重型肝炎疗效。将58例慢性乙型重型肝炎患者分为三组,核苷类似物联合人工肝治疗组、单用人工肝治疗组、单用核苷类似物治疗组,观察治疗效果。联合治疗组病死率22.22%,胆红素下降明显,白蛋白回升,凝血酶原活动度好转,HBV DNA转阴或载量下降。血浆置换治疗可降低血清HBV DNA水平。核苷类似物联合人工肝治疗可加快肝功能好转,缩短病程,降低病死率,降低血清HBV DNA水平。Abstract: To study the efficacy of nucleosides plus artificial liver support system (ALSS) on treating chronic severe hepatitis.58 patients with chronic severe hepatitis B were divided into three groups: combined treating group with nucleosides plus ALSS, ALSS treating group and nucleosides treating group.The therapeutic efficacy was observed.In combined treating group, mortality was 25%, and liver function indexes, such as bilirubin, albumin, prothrombin time activity (PTA) , and HBV DNA level, improved.Treating with nucleosides plus ALSS could accelerate the amelioration of liver function, shorten course of disease, decrease mortality and HBV DNA level.
- artificial liver support system (ALSS) /
- nucleosides /
- HBV DNA /
Villeneu JP, Condreay LD, Willems B, et al.Lamivudine treatmentfor decompensated cirrhosis resulting from chronic hepatitis B[J].Hepatology, 2000, 31∶207~210. 徐君, 张园海.拉米夫定治疗慢性乙型重型肝炎近期疗效观察[J].实用肝脏病杂志, 2004, 7 (4) ∶214-216. 吕洪敏, 杨言开, 韩涛, 等.拉米夫定治疗慢性乙型重型肝炎的近期疗效[J].中华肝脏病杂志, 2003, 11 (8) ∶500.
- 文章访问数: 2046
- HTML全文浏览量: 13
- PDF下载量: 724
- 被引次数: 0